MA30975B1 - Formulation parenterale d'anticorps anti-peptide abeta - Google Patents

Formulation parenterale d'anticorps anti-peptide abeta

Info

Publication number
MA30975B1
MA30975B1 MA31963A MA31963A MA30975B1 MA 30975 B1 MA30975 B1 MA 30975B1 MA 31963 A MA31963 A MA 31963A MA 31963 A MA31963 A MA 31963A MA 30975 B1 MA30975 B1 MA 30975B1
Authority
MA
Morocco
Prior art keywords
antibody
parenteral formulation
peptide antibody
abeta
mixture
Prior art date
Application number
MA31963A
Other languages
English (en)
Inventor
Pierre Goldbach
Hanns-Christian Mahler
Robert Mueller
Christine Wurth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39190366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30975(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30975B1 publication Critical patent/MA30975B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE FORMULATION PARENTÉRALE PHARMACEUTIQUE STABLE D'UN ANTICORPS, D'UNE MOLÉCULE D'ANTICORPS, D'UN MÉLANGE D'ANTICORPS ET/OU D'UN MÉLANGE DE MOLÉCULES D'ANTICORPS DIRIGÉS CONTRE LE PEPTIDE BÊTA-AMYLOÏDE (ABÊTA) ET UN PROCÉDÉ DE PRÉPARATION ASSOCIÉ. EN OUTRE, CETTE INVENTION CONCERNE ÉGALEMENT DES UTILISATIONS CORRESPONDANTES.
MA31963A 2006-12-11 2009-06-08 Formulation parenterale d'anticorps anti-peptide abeta MA30975B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06025590 2006-12-11

Publications (1)

Publication Number Publication Date
MA30975B1 true MA30975B1 (fr) 2009-12-01

Family

ID=39190366

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31963A MA30975B1 (fr) 2006-12-11 2009-06-08 Formulation parenterale d'anticorps anti-peptide abeta

Country Status (21)

Country Link
US (1) US20110070225A1 (fr)
EP (1) EP2094729A1 (fr)
JP (1) JP2010512356A (fr)
KR (1) KR20090104017A (fr)
CN (1) CN101553504A (fr)
AR (1) AR064220A1 (fr)
AU (1) AU2007331712A1 (fr)
BR (1) BRPI0721097A2 (fr)
CA (1) CA2671968A1 (fr)
CL (1) CL2007003583A1 (fr)
CR (1) CR10823A (fr)
EC (1) ECSP099403A (fr)
IL (1) IL198963A0 (fr)
MA (1) MA30975B1 (fr)
MX (1) MX2009006199A (fr)
NO (1) NO20092586L (fr)
PE (1) PE20081477A1 (fr)
RU (1) RU2009126420A (fr)
TW (1) TW200831133A (fr)
WO (1) WO2008071394A1 (fr)
ZA (1) ZA200904014B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CN101432302A (zh) 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
CA2631195C (fr) 2005-11-30 2016-04-05 Abbott Laboratories Anticorps monoclonaux et utilisation de ceux-ci
PT1960428E (pt) * 2005-12-12 2011-10-07 Hoffmann La Roche Anticorpos glicosilados na região variável contra beta-amilóide 4
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (fr) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CA2701793C (fr) 2007-10-05 2017-04-25 Genentech, Inc. Utilisation d'anticorps beta anti-amyloides contre les maladies occulaires
CN101970493A (zh) 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
AU2009259901B2 (en) * 2008-06-20 2016-02-04 Massachusetts Institute Of Technology Immunoglobulins with reduced aggregation
SG2014011365A (en) * 2008-09-19 2014-05-29 Hoffmann La Roche Novel antibody formulation
CN104740631B (zh) * 2008-10-29 2019-04-16 阿布林克斯公司 单域抗原结合性分子的制剂
EP2346900A1 (fr) 2008-10-29 2011-07-27 Wyeth LLC Procédés de purification de molécules de liaison d'antigène monodomaines
PE20120169A1 (es) * 2008-11-17 2012-02-29 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
EP2196476A1 (fr) * 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
WO2010069858A1 (fr) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Composition pharmaceutique
WO2010100179A2 (fr) * 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
AU2010320515B2 (en) * 2009-11-20 2013-05-02 Biocon Limited Formulations of antibody
WO2011080209A2 (fr) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Nouvelle formation d'anticorps
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
MX2012009755A (es) 2010-02-26 2012-09-12 Novo Nordisk As Composiciones que contienen anticuerpo estable.
BR112012022258A2 (pt) 2010-03-01 2016-10-25 Bayer Healthcare Llc anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
TW201144437A (en) 2010-03-03 2011-12-16 Boehringer Ingelheim Int A-beta binding polypeptides
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011147921A1 (fr) 2010-05-28 2011-12-01 Novo Nordisk A/S Compositions stables multi-doses comprenant un anticorps et un agent conservateur
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
WO2012028683A1 (fr) * 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
WO2012151247A2 (fr) * 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION POUR UN ANTICORPS ANTI-α4β7
CA2831572C (fr) 2011-05-02 2019-11-26 Immunomedics, Inc. Concentration d'ultrafiltration d'anticorps a allotype selectionne pour une administration de petit volume
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN104023743B (zh) * 2011-10-25 2017-05-03 普罗西纳治疗有限公司 抗体制剂和方法
HUE028440T2 (en) * 2012-03-08 2016-12-28 Hoffmann La Roche Abeta antibody preparation
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
RU2644214C2 (ru) * 2012-03-26 2018-02-08 Санофи СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN105025925A (zh) * 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂
KR102034757B1 (ko) 2013-07-23 2019-10-21 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
CA3093383A1 (fr) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonistes des recepteurs du glucagon et du glp-1
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
CN104946616A (zh) * 2015-05-12 2015-09-30 骏实生物科技(上海)有限公司 一种用于体外诊断试剂的通用固体稳定剂及其使用方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
CA2985718A1 (fr) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anticorps anti-recepteur de la transferrine avec une affinite adaptee
RS64263B1 (sr) * 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
KR20200035496A (ko) * 2015-09-22 2020-04-03 화이자 인코포레이티드 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN106620691B (zh) * 2015-11-04 2020-08-21 信达生物制药(苏州)有限公司 一种重组全人源抗ctla-4单克隆抗体制剂及其应用
CA3007419A1 (fr) 2015-12-30 2017-07-06 Genentech, Inc. Formulations presentant une moindre degradation des polysorbates
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用
WO2018187074A1 (fr) 2017-04-03 2018-10-11 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse
PT3672631T (pt) * 2017-08-22 2023-05-23 Biogen Ma Inc Composições farmacêuticas contendo anticorpos anti-betaamiloide
CN108373494A (zh) * 2018-02-27 2018-08-07 武汉伊艾博科技有限公司 一种防止重组蛋白质降解的保护技术
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂
CN112741804A (zh) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
EP4221750A1 (fr) * 2020-09-30 2023-08-09 Merck Sharp & Dohme LLC Protéines de liaison et fragments de liaison à l'antigène de celles-ci se liant à abêta
CN117088974B (zh) * 2023-08-14 2024-02-13 武汉健昊生物科技有限公司 一种抗体保存液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
SV2008002394A (es) * 2005-01-28 2008-02-08 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv
PT1960428E (pt) * 2005-12-12 2011-10-07 Hoffmann La Roche Anticorpos glicosilados na região variável contra beta-amilóide 4
WO2007110339A1 (fr) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Formulation d'anticorps monoclonal humain anti-igf-1r

Also Published As

Publication number Publication date
MX2009006199A (es) 2009-06-22
AU2007331712A2 (en) 2009-07-30
AR064220A1 (es) 2009-03-18
RU2009126420A (ru) 2011-01-20
AU2007331712A1 (en) 2008-06-19
CR10823A (es) 2009-08-12
KR20090104017A (ko) 2009-10-05
CL2007003583A1 (es) 2008-07-18
EP2094729A1 (fr) 2009-09-02
TW200831133A (en) 2008-08-01
IL198963A0 (en) 2011-08-01
JP2010512356A (ja) 2010-04-22
CN101553504A (zh) 2009-10-07
WO2008071394A1 (fr) 2008-06-19
ZA200904014B (en) 2010-04-28
ECSP099403A (es) 2009-07-31
CA2671968A1 (fr) 2008-06-19
BRPI0721097A2 (pt) 2014-07-01
PE20081477A1 (es) 2008-10-18
US20110070225A1 (en) 2011-03-24
NO20092586L (no) 2009-07-17

Similar Documents

Publication Publication Date Title
MA30975B1 (fr) Formulation parenterale d'anticorps anti-peptide abeta
Mainardi et al. Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the β-lactam imipenem
Hosea et al. Elucidation of distinct ligand binding sites for cytochrome P450 3A4
Dickerhof et al. Bacitracin inhibits the reductive activity of protein disulfide isomerase by disulfide bond formation with free cysteines in the substrate‐binding domain
Saric et al. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases
Harris et al. A suite of kinetically superior AEP ligases can cyclise an intrinsically disordered protein
Cantor et al. The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with β-aspartyl peptidase activity
Zvonok et al. Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis
MA31984B1 (fr) Formulation d'anticorps
Wilmouth et al. Mechanistic insights into the inhibition of serine proteases by monocyclic lactams
MY138289A (en) Pharmaceutical compositions
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
EA200100992A1 (ru) Ингибиторы фермента impdh
MA32099B1 (fr) Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci
MA30689B1 (fr) Derives de leptomycine
Marsillach et al. Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase
UA84432C2 (ru) Очищенные пептиды и соединения, которые их содержат
WO2007098184A3 (fr) Méthodes et compositions pour détection d'analytes
MA33761B1 (fr) Dispersion solide de rifaximine
Yu et al. Characterization of Dextromethorphan O-andN-Demethylation Catalyzed by Highly Purified Recombinant Human CYP2D6
WO2001059149A3 (fr) Biocapteurs peptidiques destines a la protease du charbon bacteridien
Schwarzer et al. Probing intein-catalyzed thioester formation by unnatural amino acid substitutions in the active site
MXPA04000210A (es) Conjugados quelantes mejorados.
BRPI0518300A2 (pt) derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
Roh et al. (−)-Epigallocatechin gallate inhibits hepatitis C virus (HCV) viral protein NS5B